

# BROMURO DE ACLIDINIO/FORMOTEROL

## Bibliografía

1. Global Initiative for Obstructive Lung Diseases (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD. 2016. Disponible en: <http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/>
2. National Institute for Health and Care Excellence (NICE). NICE guidelines [CG101]: Chronic obstructive pulmonary disease: Acclidinium/formoterol (Duaklir Genuair). Revisión Julio 2014. Disponible en: <https://www.nice.org.uk/guidance/cg101>
3. Duaklir Genuair. Ficha técnica autorizada. Disponible en: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/003745/WC500178413.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003745/WC500178413.pdf).
4. Duaklir Genuair. EPAR. Disponible en: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/003745/WC500178415.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003745/WC500178415.pdf).
5. Singh D, Jones PW, Bateman ED, et al. *Efficacy and safety of acclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study*. BMC Pulmonary Medicine. 2014; 14(1):178.
6. D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF, on behalf of the AUGMENT COPD study investigators. *Efficacy and safety of fixed-dose combinations of acclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study*. Respiratory Research. 2014; 15(1):123.
7. *Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Acclidinium Bromide/Formoterol Fumarate, Acclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)*. Disponible en: <http://www.clinicaltrials.gov/ct2/show/NCT01572792?term=LAC-MD-36&rank=1>.
8. *Safety and Tolerability of Acclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease*. Disponible en: <http://www.clinicaltrials.gov/ct2/show/NCT01437540?term=LAC-MD-32&rank=1>